BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 4, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» Shenzhen Zhongge Biotechnology patents new IRAK-4 inhibitors
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Musculoskeletal
Shenzhen Zhongge Biotechnology patents new IRAK-4 inhibitors
July 2, 2024
No Comments
Shenzhen Zhongge Biotechnology Co. Ltd. has disclosed interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors and/or degraders reported to be useful for the treatment of cancer, psoriasis, systemic lupus erythematosus, osteoarthritis, graft-vs.-host disease, rheumatoid arthritis, irritable bowel syndrome and chronic obstructive pulmonary disease, among others.
BioWorld Science
Musculoskeletal
Patents